GlassScriptPhysician profile
Seth J Herbst
NPI 1730144023
$4,814.75
in general payments reported to CMS, 2019-2025
47 companies · $663 in 2025
The $663 reported for 2025 was more than what 86% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,035 · 2020: $110 · 2021: $654 · 2022: $581 · 2023: $966 · 2024: $805 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,381 · Education: $53.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,381.31 |
| Education | $53.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $520.08 | 2023-2025 | Myfembree, Gemtesa |
| Abbvie INC. | $381.83 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $360.46 | 2021-2025 | |
| Astellas Pharma US INC | $353.18 | 2019-2025 | Veozah |
| Myovant Sciences INC. | $303.13 | 2021-2022 | |
| Hologic Sales and Service, LLC | $281.45 | 2019-2025 | Aptima, Thinprep 2000 Processor, Novasure |
| Therapeuticsmd, INC. | $268.71 | 2019-2022 | |
| Channel Medsystems, INC. | $219.80 | 2023 | |
| Medtronic, INC. | $179.74 | 2023 | Truclear |
| Millicent US INC | $174.33 | 2020-2025 | Femring, Intrarosa |
| Pfizer INC. | $156.00 | 2019-2023 | |
| Allergan, INC. | $142.68 | 2019 | |
| Radius Health, INC. | $138.92 | 2019-2024 | Tymlos |
| Kvk-Tech, INC. | $135.58 | 2019-2020 | |
| Novo Nordisk INC | $131.40 | 2019-2024 | Wegovy |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $112.51 | 2019-2024 | Advincula Delineator Uterine Manipulator, Summit Doppler |
| Bayer Healthcare Pharmaceuticals INC. | $109.28 | 2021-2025 | |
| Exact Sciences Corporation | $102.34 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $56.62 | 2019-2025 | Evenity |
| Lilly USA, LLC | $47.40 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Lupin INC. | $45.49 | 2019-2021 | |
| Exeltis, USA INC. | $40.36 | 2024-2025 | Slynd |
| Agile Therapeutics, INC. | $36.15 | 2021-2023 | Twirla |
| Vivus LLC | $36.03 | 2019-2020 | |
| Scynexis, INC. | $34.66 | 2022 | |
| Daiichi Sankyo INC. | $33.70 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $33.36 | 2024 | |
| Covidien LP | $33.03 | 2019 | |
| Organon LLC | $29.79 | 2022-2023 | Nexplanon |
| Shield Therapeutics INC | $28.54 | 2023 | Accrufer |
| Ascend Therapeutics US, LLC | $26.46 | 2021-2022 | |
| Avion Pharmaceuticals | $24.41 | 2021-2022 | |
| Evofem Biosciences, INC. | $24.05 | 2021 | |
| Ibsa Pharma INC. | $20.94 | 2023 | Tirosint, Licart |
| Dexcom, INC. | $20.35 | 2025 | Dexcom G6 Transmitter |
| Intuitive Surgical, INC. | $18.36 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $17.37 | 2021 | |
| Biogen, INC. | $17.25 | 2025 | Zurzuvae |
| Avanos Medical | $17.03 | 2019 | |
| Boston Scientific Corporation | $16.67 | 2021 | |
| Baxter Healthcare | $16.49 | 2025 | Perclot |
| Vertical Pharmaceuticals, LLC | $15.36 | 2019 | |
| Amag Pharmaceuticals, INC. | $15.28 | 2019 | |
| Mylan Pharmaceuticals INC. | $15.09 | 2021 | |
| Mycovia Pharmaceuticals, INC. | $14.80 | 2023 | Vivjoa |
| Meditrina | $8.29 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Herbst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.